Medacta reports 9.7% revenue growth in first half of 2026

Medacta reported first-half 2026 constant-currency revenue growth of 9.7%, adjusted EBITDA of €97 million, and a 27.8% adjusted EBITDA margin. Growth was driven by double-digit expansion in Asia Pacific and EMEA, while North America slowed amid softer U.S. demand and a Spine sales-channel transition. The company reiterated full-year constant-currency revenue growth guidance of 10%-14% and expects adjusted EBITDA margin expansion of about 50bps, although net profit declined year over year due to a prior-period one-off gain.

Analysis

MOVE’s setup is more attractive as an execution rerating than as a pure growth story: sustained operating leverage alongside procedure-volume growth would justify a narrowing of its valuation discount versus larger orthopedics peers such as SYK, ZBH and JNJ. The key question for the next 1-3 months is whether the U.S. Spine channel reset is a temporary distribution disruption or evidence that smaller suppliers are losing purchasing leverage as hospitals and ASCs consolidate. Evidence that new U.S. surgeon adoption converts into repeat implant utilization would support a higher-quality, recurring share-gain thesis.

The most important second-order benefit is to MOVE’s mix. Navigation, minimally invasive techniques and differentiated knee products can raise implant pull-through and reduce reliance on price-competitive legacy hardware; if adoption scales, gross-margin expansion could exceed the stated EBITDA trajectory over the next 6-18 months. Conversely, large competitors can bundle implants, robots and service contracts with IDNs, making independent surgeon enthusiasm insufficient if procurement committees favor one-stop vendors.

Do not use APP or SMCI as read-throughs: their inclusion appears promotional and has no fundamental connection to MOVE’s orthopedic demand, earnings quality or valuation. The contrarian risk is that investors may capitalize the stronger non-U.S. growth too aggressively while overlooking U.S. channel-transition costs; the thesis is falsified by a second consecutive period of decelerating North American organic growth, reduced full-year outlook, or margin expansion failing to materialize despite higher sales.

Key Decisions for Investors

• Initiate a small long MOVE position only after management confirms that U.S. Spine distributor/channel conversion is substantially complete and reiterates full-year profitability objectives; target a 6-12 month rerating toward peer-relative multiples if North America reaccelerates. Size modestly because liquidity and exchange access may be more constrained than U.S.-listed peers.
• Prefer a relative-value expression: long MOVE / short ZBH in equal sector-beta-adjusted dollars over 6-12 months, conditional on MOVE demonstrating U.S. growth stabilization. The spread captures potential innovation-led share gains while reducing broad elective-procedure and reimbursement exposure.
• Set a downside stop/reassessment trigger at either a full-year growth-guide cut or North American growth remaining below the company’s consolidated run-rate at the next results. Those outcomes would indicate that the channel issue is structural rather than transitional.
• Avoid APP, SMCI and any trade based on the article’s embedded AI-stock promotion; it provides no actionable linkage to MOVE and should not influence position sizing.